Subtopic Deep Dive

Coagulation Factor XII in Hereditary Angioedema
Research Guide

What is Coagulation Factor XII in Hereditary Angioedema?

Coagulation Factor XII (FXII) drives hereditary angioedema (HAE) pathogenesis through contact pathway activation, generating bradykinin in C1-INH deficient patients.

FXII initiates the intrinsic coagulation pathway and kallikrein-kinin system, leading to excessive bradykinin production causing HAE attacks. Research focuses on FXII mutations, contact activation, and targeted inhibitors as prophylactics. Over 600 papers cite key works like Cicardi et al. (2014, 634 citations) on HAE classification.

15
Curated Papers
3
Key Challenges

Why It Matters

FXII-targeted therapies like garadacimab reduce HAE attack frequency by 87% in phase 2 trials, offering prophylaxis independent of C1-INH (Busse et al., 2020). Contact system modulation prevents bradykinin-mediated edema without anticoagulant risks (Colman and Schmaier, 1997). These advances guide guidelines for managing type I/III HAE, impacting 1 in 50,000 patients (Cicardi et al., 2014; Longhurst and Cicardi, 2012).

Key Research Challenges

FXII Mutation Identification

Detecting rare FXII gain-of-function mutations in HAE-nC1-INH remains challenging due to phenotypic overlap with type I/II HAE. Sequencing studies reveal limited variants despite bradykinin pathway links (Bafunno et al., 2017). Functional assays are needed to confirm pathogenicity.

Specific FXII Inhibition

Developing FXIIa inhibitors that block bradykinin generation without impairing coagulation or fibrinolysis is complex. Preclinical models show polyphosphate-FXII interactions drive activation (Colman and Schmaier, 1997). Clinical translation faces dosing and safety hurdles (Moreau et al., 2005).

Translating Contact Pathway

Linking surface-mediated FXII activation to clinical HAE triggers like stress or infection requires better biomarkers. Consensus guidelines highlight unmet needs in attack prediction (Cicardi et al., 2014). Longitudinal studies are sparse for polyphosphate roles.

Essential Papers

1.

Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

A Agostoni, Emel Aygören‐Pürsün, Karen Binkley et al. · 2004 · Journal of Allergy and Clinical Immunology · 639 citations

2.

Classification, diagnosis, and approach to treatment for angioedema: consensus report from the <scp>H</scp>ereditary <scp>A</scp>ngioedema <scp>I</scp>nternational <scp>W</scp>orking <scp>G</scp>roup

Marco Cicardi, Werner Aberer, Aleena Banerji et al. · 2014 · Allergy · 634 citations

Abstract Angioedema is defined as localized and self‐limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoacti...

3.

Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes

Robert W. Colman, Alvin H. Schmaier · 1997 · Blood · 585 citations

physiologic reactions of vascular biology.Last, this presentation will point to possible new therapeutic strategies to treat HE KALLIKREIN-KININ system was first recognized as a plasma and tissue p...

4.

The Kallikrein-Kinin System: Current and Future Pharmacological Targets

Marie Eve Moreau, Nancy Garbacki, Giuseppe A. Molinaro et al. · 2005 · Journal of Pharmacological Sciences · 457 citations

The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precu...

5.

Hereditary angio-oedema

Hilary Longhurst, Marco Cicardi · 2012 · The Lancet · 325 citations

6.

US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema

Paula J. Busse, Sandra C. Christiansen, Marc A. Riedl et al. · 2020 · The Journal of Allergy and Clinical Immunology In Practice · 316 citations

7.

Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema

Valeria Bafunno, Davide Firinu, Maria D’Apolito et al. · 2017 · Journal of Allergy and Clinical Immunology · 292 citations

Reading Guide

Foundational Papers

Start with Colman and Schmaier (1997, 585 citations) for contact system basics linking FXII to bradykinin, then Agostoni et al. (2004, 639 citations) for HAE workshop consensus on C1-INH deficiency.

Recent Advances

Study Busse et al. (2020, 316 citations) for FXII inhibitor guidelines and Bafunno et al. (2017, 292 citations) on novel HAE mutations beyond FXII.

Core Methods

Core techniques: chromogenic assays for FXIIa activity, genetic panels for F12 mutations, and randomized trials of monoclonal FXII inhibitors (Cicardi et al., 2014; Moreau et al., 2005).

How PapersFlow Helps You Research Coagulation Factor XII in Hereditary Angioedema

Discover & Search

Research Agent uses searchPapers('FXII hereditary angioedema bradykinin') to retrieve Cicardi et al. (2014, 634 citations), then citationGraph reveals Colman and Schmaier (1997) as foundational contact system work, while findSimilarPapers expands to FXII inhibitors; exaSearch uncovers trial data on garadacimab.

Analyze & Verify

Analysis Agent applies readPaperContent on Busse et al. (2020) guidelines to extract FXII therapy efficacy, verifyResponse with CoVe cross-checks bradykinin claims against Colman (1984), and runPythonAnalysis plots attack reduction stats from trial data using pandas; GRADE grading scores evidence as high for prophylaxis recommendations.

Synthesize & Write

Synthesis Agent detects gaps in FXII-polyphosphate links via contradiction flagging across Moreau et al. (2005) and recent trials; Writing Agent uses latexEditText for HAE pathway revisions, latexSyncCitations integrates Agostoni et al. (2004), latexCompile generates polished reviews, and exportMermaid visualizes contact activation cascades.

Use Cases

"Analyze FXII inhibitor trial data for HAE attack rates"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Busse et al. 2020 trial stats) → bar chart of 87% reduction and statistical p-values.

"Draft LaTeX review on FXII in HAE with contact pathway diagram"

Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Cicardi 2014) + exportMermaid (bradykinin cascade) → latexCompile → camera-ready PDF.

"Find open-source code for FXII activation simulations"

Research Agent → paperExtractUrls (Colman 1997) → paperFindGithubRepo → githubRepoInspect → verified Python model of kininogen binding kinetics.

Automated Workflows

Deep Research workflow scans 50+ HAE papers via searchPapers → citationGraph → structured report on FXII evolution (Agostoni 2004 to Busse 2020). DeepScan's 7-step chain with CoVe verifies bradykinin claims in Cicardi (2014). Theorizer generates hypotheses on FXII-polyphosphate triggers from Colman/Schmaier (1997).

Frequently Asked Questions

What defines FXII's role in HAE?

FXII activates the contact pathway, converting prekallikrein to kallikrein that generates bradykinin, causing edema in C1-INH deficient HAE (Colman and Schmaier, 1997; Cicardi et al., 2014).

What methods study FXII in HAE?

Methods include genetic sequencing for mutations, plasma kallikrein assays, and FXIIa inhibitor trials; consensus uses ELISA for bradykinin levels (Busse et al., 2020; Bafunno et al., 2017).

What are key papers on FXII-HAE?

Cicardi et al. (2014, 634 citations) classifies HAE; Colman and Schmaier (1997, 585 citations) details contact system; Busse et al. (2020, 316 citations) guides FXII therapies.

What open problems exist?

Unresolved issues include FXII biomarkers for attack prediction, polyphosphate trigger mechanisms, and long-term safety of FXII inhibitors beyond phase 2 (Moreau et al., 2005; Longhurst and Cicardi, 2012).

Research Coagulation, Bradykinin, Polyphosphates, and Angioedema with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Coagulation Factor XII in Hereditary Angioedema with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers